Mental healthcare company focusing on accelerating patient access and experience to evidence-based innovation in mental health care COMPASS Pathways Plc. (NASDAQ: CMPS) has entered into a long-term strategic partnership to launch The Center for Mental Health Research and Innovation to accelerate psychedelic research and develop new forms of mental health therapies in the UK.
COMPASS entered into partnership with South London and Maudsley NHS Foundation Trust (SLaM) to provide patient access to cutting edge research studies in several areas of high unmet need in mental health.
Maudsley NHS Foundation Trust is the largest mental health trust in the UK National Health Service (NHS) and the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London.
The company’s chairman and CEO, George Goldsmith, says the center will accelerate research of emerging psychedelic therapies, assist training and certification of therapists, evaluate real-world evidence and prototype digital technologies to enable personalized, predictive and preventative care models.
“In 2021, the UK Government included mental health care as a core pillar of its Life Sciences Vision a signal of how critical an issue this is becoming. We are grateful to be able to play a part in this, and to be working with SLaM and the IoPPN, UK leaders in patient care and research in mental health. The Centre will accelerate the integration of innovative psychedelic therapies into the NHS following regulatory approval and reimbursement. It is a key part of our strategy to work with health systems to develop innovative evidence-based therapies, and ensure they reach those who might benefit from them as quickly as possible,” said the CEO.